Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
Garcia-Manero, G, Gore, S D, Kambhampati, S, Scott, B, Tefferi, A, Cogle, C R, Edenfield, W J, Hetzer, J, Kumar, K, Laille, E, Shi, T, MacBeth, K J, Skikne, B
Published in Leukemia (01.04.2016)
Published in Leukemia (01.04.2016)
Get full text
Journal Article
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
List, A F, Bennett, J M, Sekeres, M A, Skikne, B, Fu, T, Shammo, J M, Nimer, S D, Knight, R D, Giagounidis, A
Published in Leukemia (01.05.2014)
Published in Leukemia (01.05.2014)
Get full text
Journal Article
P571: ORAL AZACITIDINE VS MIDOSTAURIN AS MAINTENANCE TREATMENT FOR FLT3 MUTANT ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION: AN INDIRECT TREATMENT COMPARISON
Oliva, E. N., Chen, C., Rahim, S. N., Seuro, B., Vasconcelos, A., Gaugler, L., Skikne, B., Prebet, T., Cameron, H., Beach, C., Thompson, G.
Published in HemaSphere (01.06.2022)
Published in HemaSphere (01.06.2022)
Get full text
Journal Article
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
List, A F, Bennett, J M, Sekeres, M A, Skikne, B, Fu, T, Shammo, J M, Nimer, S D, Knight, R D, Giagounidis, A
Published in Leukemia (01.12.2015)
Published in Leukemia (01.12.2015)
Get full text
Journal Article
P498: CLINICAL AND BIOLOGICAL MARKERS ASSOCIATED WITH LONG‐TERM SURVIVAL FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN REMISSION AFTER CHEMOTHERAPY IN THE QUAZAR AML‐001 TRIAL OF ORAL AZACITIDINE
Wei, A. H., Döhner, H., Sayar, H., Ravandi, F., Montesinos, P., Dombret, H., Selleslag, D., Porkka, K., Jang, J.‐H., Skikne, B., Beach, C., Prebet, T., Zhang, G., Risueño, A., Ugidos Guerrero, M., See, W. L., Menezes, D., Roboz, G. J.
Published in HemaSphere (01.06.2022)
Published in HemaSphere (01.06.2022)
Get full text
Journal Article
115 MDS-005 STUDY: EFFECT OF BASELINE ENDOGENOUS EPO ON RBC TRANSFUSION INDEPENDENCE (RBC-TI) IN LENALIDOMIDE-TREATED PATIENTS WITH LOW/INTERMEDIATE-1-RISK MDS WITHOUT DEL(5Q)
Santini, V, Li, J.S, Swern, A.S, Almeida, A, Giagounidis, A, Fu, T, Hoenekopp, A, Beach, C.L, Skikne, B, Fenaux, P
Published in Leukemia research (01.04.2015)
Published in Leukemia research (01.04.2015)
Get full text
Journal Article
116 THE EFFECT OF LENALIDOMIDE ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH MDS: RESULTS FROM THE MDS-005 TRIAL
Santini, V, Almeida, A, Giagounidis, A, Bartiromo, C, Hoenekopp, A, Guo, S, Beach, C.L, Altincatal, A, Wu, C, Skikne, B, Zhong, J, Hu, X.H, Fenaux, P
Published in Leukemia research (01.04.2015)
Published in Leukemia research (01.04.2015)
Get full text
Journal Article
P-197 A study of gastric acid pH modulation on the pharmacokinetics of oral azacitidine (CC-486) in subjects with hematologic malignancies
Laille, E, Conkling, P, Kolibaba, K, Morris, J, Rifkin, R, Kingsley, E, Wang, X, Dong, Q, Kellerman, A, Skikne, B
Published in Leukemia research (01.05.2013)
Published in Leukemia research (01.05.2013)
Get full text
Journal Article
Fatal chemotherapy-induced encephalopathy following high-dose therapy for metastatic breast cancer: a case report and review of the literature
COSSAART, N, SANTACRUZ, K. S, PRESTON, D, JOHNSON, P, SKIKNE, B. S
Published in Bone marrow transplantation (Basingstoke) (01.01.2003)
Published in Bone marrow transplantation (Basingstoke) (01.01.2003)
Get full text
Journal Article
181 Oral azacitidine is bioavailable and reduces DNA methylation at low doses in extended schedules: Phase I study results
Laille, E, Shi, T, Garcia-Manero, G, Gore, S.D, Cogle, C.R, Giordano, H, MacBeth, K.J, Skikne, B
Published in Leukemia research (01.05.2011)
Published in Leukemia research (01.05.2011)
Get full text
Journal Article
Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure
Ahluwalia, N, Skikne, B S, Savin, V, Chonko, A
Published in American journal of kidney diseases (01.10.1997)
Published in American journal of kidney diseases (01.10.1997)
Get more information
Journal Article